HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 9, 2015, Pages 1061-1064

  Ben Baruch, Noa Efrat ^a   Bose, Ron ^b,c   Kavuri, Shyam M ^b,c,d   Ma, Cynthia X ^b,c   Ellis, Matthew J ^b,c,d  

^a KAPLAN MEDICAL CENTER   (Israel)

^b Washington University in St Louis School of Medicine   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; LAPATINIB; LETROZOLE; LOPERAMIDE; NAVELBINE; NERATINIB; PROGESTERONE RECEPTOR; PROTEIN MDM2; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; ASCITES; BONE METASTASIS; BREAST BIOPSY; BREAST CARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CHYLE; FEMALE; FUNCTIONAL STATUS; GENE MUTATION; GERMLINE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; JAUNDICE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER METASTASIS; LOADING DRUG DOSE; MASTECTOMY; NEXT GENERATION SEQUENCING; OBSTRUCTIVE JAUNDICE; ONCOGENE MYC; OVARIECTOMY; PLEURA EFFUSION; PROPHYLAXIS; TREATMENT RESPONSE; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; RETREATMENT; SECONDARY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CAPECITABINE; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LIVER NEOPLASMS; MASTECTOMY; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-2; RETREATMENT;

EID: 84941760766     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0131     Document Type: Article

References (15)

1. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012;490:61-70.
2. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-237.
3. Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 2012;109:14476-14481.
4. Kancha RK, von Bubnoff N, Bartosch N, et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE 2011;6:e26760.
5. Rexer BN, Ghosh R, Narasanna A, et al. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res 2013;19:5390-5401.
6. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
7. Ali SM, Alpaugh RK, Downing SR, et al. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol 2014;32:e88-91.
8. Chow LW, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer 2013;108:1985-1993.
9. Awada A, Dirix L, Manso Sanchez L, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2013;24:109-116.
10. Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with ErbB2-positive breast cancer [abstract]. Cancer Res 2011;71(24 Suppl):Abstract P1-12-09.
11. Gandhi L, Bahleda R, Tolaney SM, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014;32:68-75.
12. Gajria D, King T, Pannu H, et al. Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: a phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer [abstract]. Cancer Res 2011;71(24 Suppl):Abstract PD 09-08.
13. Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol 2013;72:1205-1212.
14. The Cancer Genome Atlas Consortium. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
15. The Cancer Genome Atlas Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-322.